A practical reference on Melanocortin receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-07-31. Anything still debated is marked as such rather than presented as settled.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its design combines the ACTH(4-7) core fragment with a C-terminal Pro-Gly-Pro extension, a modification intended to improve stability and prolong activity. The molecule is hydrophilic, carries no lipid chains or glycosylation, and has a theoretical mass just over 810 daltons in its free form. All seven residues are proteinogenic amino acids, so no non-natural building blocks appear in the backbone. A free N-terminal methionine and C-terminal proline define the unmodified parent peptide.
The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.
Pharmacological accounts link semax to melanocortin signalling and to modulation of neurotrophic factor expression, particularly brain-derived neurotrophic factor and nerve growth factor. Much of this evidence comes from rodent studies using intranasal delivery, a route chosen because it allows peptides to reach the central nervous system with limited systemic exposure. Whether the same mechanisms operate in humans at comparable magnitude remains an open question. The precise receptor or receptors responsible for the reported behavioural and neuroprotective effects have not been conclusively identified.
Clinical reports describe use in ischaemic stroke, transient ischaemic attack, optic nerve conditions, and cognitive complaints, but most of these studies are small and were conducted in a single region. Systematic reviews have generally described the evidence base as limited in size and variable in methodological quality. Randomised controlled data suitable for international regulatory assessment are scarce. As a result, major treatment guidelines outside Russia do not include the peptide, and interest in it remains largely research-driven rather than routine clinical.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is described in the literature as an analogue of the ACTH(4–10) fragment, a short N-terminal portion of adrenocorticotropic hormone that retains some neurotropic activity without the full hormonal effects of the parent peptide. The molecule carries a methionine residue at the N-terminus and two proline residues near the C-terminus, features that shape both its interactions with receptor systems and its chemical stability. The free peptide corresponds to the formula C37H51N9O10S and a molecular mass near 813.9 Da.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | ACTH(4-7) analogue |
| Sequence | Met-Glu-His-Phe-Pro-Gly-Pro | Free N terminus, unmodified side chains |
| Molecular weight | 813.9 Da | Free base; salt forms differ |
| Appearance | White to off-white powder | Lyophilised solid |
| Solubility | Freely soluble in water | Hydrophilic; polar solvents preferred |
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.
Laboratory work points toward modulation of neurotrophic signaling, particularly expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal tissue. Studies also describe effects on monoamine turnover, inflammatory mediators, and oxidative markers. These observations come mainly from animal models and cultured cells, so the causal chain in humans is not firmly established. Whether the reported molecular changes translate into measurable clinical benefit is an open question. Reviews generally present the mechanism as plausible rather than demonstrated.
Clinical evidence consists largely of small trials with modest sample sizes, often without independent replication. Reported endpoints include cognitive scores, recovery after stroke, and visual function, but study designs vary widely and few trials meet contemporary reporting standards. Systematic reviewers have noted a high risk of bias in several of these reports. No large multicenter trial conducted outside Russia has been published. The compound is therefore best described as investigational in most jurisdictions, with its clinical role still unresolved.
该化合物于二十世纪八十年代在俄罗斯被开发，相关工作由俄罗斯科学院分子遗传学研究所的研究团队主导。开发目标并非复制 ACTH 的完整激素活性，而是寻找保留其神经作用方向、同时去除促肾上腺皮质激素释放效应的短肽片段。研究记录显示，这一方向促成了多个相关短肽的合成与筛选，而 Semax 是其中被研究最广泛的一个。当地文献常以 Семакс 这一名称指代它。
研究兴趣主要集中在神经营养因子相关的路径上，包括脑源性神经营养因子与神经生长因子的表达变化。部分实验报告称在特定条件下观察到这些因子的水平上升，但具体信号通路和剂量依赖关系仍未完全厘清。多数公开数据来自细胞模型和动物实验，人体对照研究数量有限。因此，该化合物的作用机制在文献中属于活跃讨论，而非已经确立的定论。
Semax 是一种人工合成的七肽，氨基酸序列为 Met-Glu-His-Phe-Pro-Gly-Pro，单字母缩写记作 MEHFPGP。它被归类为促肾上腺皮质激素片段 ACTH(4-10) 的结构类似物，但并不天然存在于生物体内。母体片段 ACTH(4-10) 的序列为 Met-Glu-His-Phe-Arg-Trp-Gly，Semax 替换了中间两个残基，并在羧基端延长了 Pro-Gly-Pro 三肽。这种延长被普遍认为能提升分子对肽酶的耐受性。
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was derived from the ACTH(4-10) fragment, a short segment of adrenocorticotropic hormone that lacks the hormonal activity associated with the full-length peptide. Researchers at the Institute of Molecular Genetics in Moscow developed the compound during the 1980s. It has been registered as a pharmaceutical product in Russia and several neighbouring countries, where it is supplied as a nasal solution, and it is also sold internationally as a research chemical.
The proposed mechanism centres on neurotrophic signalling rather than direct receptor activation. Semax is reported to increase expression of brain-derived neurotrophic factor and nerve growth factor in several brain regions, and to shift the balance between excitatory and inhibitory neurotransmitter systems. Interaction with melanocortin receptors has been suggested because of the parent ACTH fragment. Many of these findings come from rodent studies, and the extent to which they translate to human physiology remains an open question.
Big dick energy Body dysmorphic disorder Erection Human penis Human vaginal size Penile dysmorphic disorder Penis enlargement Penis envy Phalloplasty Sexual selection in humans The Third Chimpanzee Why Is Sex Fun?
=== 1988 to 2011: Reduced again but back on operations === At the end of the Cold War, the TA had a strength of 72,823, including 3,297 in the Home Service Force (HSF). in the 1991 Gulf War 205 Scottish General Hospital was mobilised as a unit based in Riyadh, Saudi Arabia, and a number of TA staff officers and others volunteered and served during the conflict, either in supporting roles in Germany or within 1 (UK) Armoured Division in the Middle East. In December 1991, as part of the reductions in Options for Change, it was announced that the TA's establishment was to be reduced to 63,000, while the HSF element was to be disbanded. In July 1994, this was further reduced to 59,000. The Reserve Forces Act of May 1996 was a landmark reform, making it much easier to call out any element of the Reserves at the behest of the Secretary of State for a range of purposes including 'protection of life or property' well short of the criteria for Queen's Order (e.g. 'great emergency', 'imminent national danger'). It also provides protection in employment law for members' civilian jobs should they be mobilised. This has led to the Army Reserve increasingly providing routine support for the Regular Army overseas including the delivery of composite units to release regular units from standing liabilities; including Bosnia, Kosovo, Cyprus and the Falkland Islands. Some 2,800 TA personnel volunteered for and deployed on Operation Resolute from 1995 to 1998, the UK's contribution to the NATO mission to enforce peace in the Former Yugoslavia.
== Awards and honours == Hopkins was elected a Foreign Associate of the National Academy of Sciences (USA) in 1924. During his life, in addition to the Nobel Prize, Hopkins was awarded the Royal Medal of the Royal Society in 1918, the Cameron Prize for Therapeutics of the University of Edinburgh in 1922, and the Copley Medal of the Royal Society in 1926. Other significant honours were his election in 1905 as a Fellow of the Royal Society (FRS), Great Britain's most prestigious scientific organisation; his knighthood by King George V in 1925; and the award in 1935 of the Order of Merit, Great Britain's most exclusive civilian honour. From 1930 to 1935, he served as president of the Royal Society and, in 1933, served as president of the British Association for the Advancement of Science. He was elected to the American Philosophical Society in 1937.
=== Zymogen activation === Zymogens are the usually inactive precursors of an enzyme. If the digestive enzymes were active when synthesized, they would immediately start chewing up the synthesizing organs and tissues. Acute pancreatitis is such a condition, in which there is premature activation of the digestive enzymes in the pancreas, resulting in self-digestion (autolysis). It also complicates postmortem investigations, as the pancreas often digests itself before it can be assessed visually. Zymogens are large, inactive structures, which have the ability to break apart or change into the smaller activated enzymes. The difference between zymogens and the activated enzymes lies in the fact that the active site for catalysis of the zymogens is distorted. As a result, the substrate polypeptide cannot bind effectively, and proteolysis does not occur. Only after activation, during which the conformation and structure of the zymogen change and the active site is opened, can proteolysis occur.
Sources: en.wikipedia.org
Sanlúcar de Barrameda is one of the three original towns forming the "triangle of xérès", or sherry-producing towns. (The other two are Jerez de la Frontera, for which sherry is named, and El Puerto de Santa María.) Although a seaside town, Sanlúcar de Barrameda is also home to the oldest horse races in Spain and some of the oldest in Europe. The races take place just before sunset along the beach at the mouth of the river Guadalquivir every August before thousands of spectators. Contested at distances of 1500 m and 1800 m, these were the first regulated horse races in Spain; the riders wear distinctive colours and caps. Other annual events include the Sanlúcar Tapas Fair, a local gastronomy competition; the Feria de la Manzanilla in late May, which is held at the beginning of the Noches de Bajo de Guía flamenco season; classical and jazz festivals; and the occasional concert by a major act. The city is also known for the Romería de El Rocío pilgrimage, one of the more popular expressions of the Roman Catholic faith; it can be compared to the pilgrimages to Santiago or Lourdes. Sanlúcar has had since ancient times a popular taste for bullfighting and has given the world of bullfighting several well-known bullfighters including Manuel Hermosilla y Llanera, José Martínez Ahumada ("Limeño"), Francisco Ojeda González ("Paco" Ojeda), Julio Vega Rodríguez ("Marismeño"), José Luis Parada, and Manuel Rodríguez Blanco ("El Manguin").
The Original Chubby Burger which is made on sesame seed bun, and comes with Chubby Mayo (Hellmann's Mayo), and lettuce. The Spicy Habanero Chicken Burger is made on a seeded bun with a spicy chicken portion, and comes with jalapeño aioli, lettuce and tomato. BLT Chubby Burger is made on a 7-grain bun, and comes with Chubby Mayo (Hellmann's Mayo), two slices of bacon, lettuce, and tomato. These can be ordered by themselves, or in combos. They also offer all white-meat chicken strips which come in either 3 or 5, by themselves, or in combos. The chicken strips may also be ordered in wraps such as the "Chipotle Chicken wrap" and the "Bacon Ranch wrap". Some locations used to offer fried chicken bone-in pieces however, the bone in chicken was discontinued as an optional item in 2020.
=== Bio-Chemicals business === Biosimilars Monoclonal Antibodies Amino acids, nucleic acids and related compounds, health care products and other active pharmaceutical ingredients Vitamins, minerals, peptides and plant growth regulators
Everton, one of the top clubs in the English football league, were champions of the 1962–63 season, and it was done, according to a national newspaper investigation, with the help of Benzedrine. Word spread after Everton's win that the drug had been involved. The newspaper investigated, cited where the reporter believed it had come from, and quoted the goalkeeper, Albert Dunlop, as saying:
In the afternoon of 23 September, Xi Jinping boarded an Air China plane and left Beijing for Washington, D.C. He was accompanied by his wife Peng Liyuan, as well as Chinese Communist Party General Office director Cai Qi and Central Foreign Affairs Commission Office director and foreign minister Wang Yi. President Trump and First Lady Melania Trump left the White House at 16:39 EDT (UTC-4:00), and later arrived at Joint Base Andrews in Maryland. Xi's Air China plane landed at the base at 17:39, and a red carpet was placed for the Chinese delegation, who were also greeted by battery salute, three color teams carrying American and Chinese flags, and platoons from each military service. Trump personally greeted Xi, the first time the US President has greeted a foreign leader except the Pope at the base since John F. Kennedy met British prime minister Harold Macmillan in 1962. The United States Air Force Band played the national anthems of China and the United States and a 21-gun salute was fired on site. Two Rockwell B-1 Lancer bombers flew overhead to celebrate Xi's arrival. Trump walked Xi to his car, and afterwards departed to the Marine One by the presidential state car for a flight back to the White House.
Sources: en.wikipedia.org
It is a synthetic seven-amino-acid peptide built from the ACTH(4-7) sequence plus a Pro-Gly-Pro tail. It belongs to the family of short ACTH fragments studied for nervous-system effects. Its backbone contains only standard amino acids.
It contains the 4-7 fragment of adrenocorticotropic hormone extended at the C terminus. That truncation removes the region associated with steroidogenic activity. The design intent was to keep neurotrophic properties while avoiding full hormonal effects.
No natural source of the intact heptapeptide is known. It is produced by solid-phase peptide synthesis. Some related ACTH fragments arise as hormone processing products, but the Pro-Gly-Pro extension is a designed addition rather than a natural sequence.
It is described as a synthetic analogue of the ACTH(4–10) fragment, a short segment of adrenocorticotropic hormone. Its sequence differs from that fragment and includes two proline residues, which influence stability and behaviour in solution.